Integra LifeSciences (IART) Projected to Post Earnings on Wednesday

Key Points

• Integra LifeSciences is expected to report Q3 2026 results before the market opens on October 21. Analysts forecast EPS of $0.563 and revenue of $415.36 million, compared with company guidance of $0.530–$0.610 EPS.
• The company exceeded expectations in its latest quarter, reporting $0.56 EPS versus the $0.48 consensus and revenue of $418.76 million versus $417.54 million expected.
• Analyst sentiment remains cautious: Integra has a consensus “Reduce” rating and an average price target of $17.29, while its shares recently opened at $13.85, down 0.9%.

Integra LifeSciences (NASDAQ:IART - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect the company to post earnings of $0.5630 per share and revenue of $415.36 million for the quarter. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Individuals can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.48 by $0.08. The business had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. On average, analysts expect Integra LifeSciences to post $2.47 EPS for the current fiscal year and $2.58 EPS for the next fiscal year.

Integra LifeSciences Stock Down 0.9%

Integra LifeSciences stock opened at $13.85 on Wednesday. The stock has a market cap of $1.08 billion, a P/E ratio of -153.87, a P/E/G ratio of 0.72 and a beta of 1.21. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $20.49. The company's 50-day moving average price is $16.07 and its two-hundred day moving average price is $15.40.

Analysts Set New Price Targets

Several research firms have recently commented on IART. Wall Street Zen downgraded Integra LifeSciences from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 price target for the company in a report on Thursday, June 18th. Weiss Ratings downgraded Integra LifeSciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 2nd. Truist Financial upgraded Integra LifeSciences to a "hold" rating in a research note on Thursday, October 1st. Finally, Wells Fargo & Company set a $15.00 price objective on Integra LifeSciences in a report on Saturday, October 3rd. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Integra LifeSciences has a consensus rating of "Reduce" and an average target price of $17.29.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company's products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.